# Pacritinib in CMML

> **NCT06159491** · PHASE1,PHASE2 · RECRUITING · sponsor: **Douglas Tremblay** · enrollment: 26 (estimated)

## Conditions studied

- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT06159491
- **Lead sponsor:** Douglas Tremblay
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-18
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06159491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06159491, "Pacritinib in CMML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06159491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*